Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

1431468-36-8Cabozantinib Impurity 3

● Auf Lager

Katalog-Nr.::	VE0028099
CAS-Nr.::	1431468-36-8
Summenformel::	C17H14F2N2O2
Molare Masse::	316.30 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 1431468-36-8

Parent drug

Cabozantinib

IUPAC-Name

N,N‘-Bis(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

Pharmacopeial Synonyms

N/A

Synonyme

N/A

SMILES

O=C(NC1=CC=C(C=C1)F)C2(C(NC3=CC=C(C=C3)F)=O)CC2

InChI

InChI=1S/C17H14F2N2O2/c18-11-1-5-13(6-2-11)20-15(22)17(9-10-17)16(23)21-14-7-3-12(19)4-8-14/h1-8H,9-10H2,(H,20,22)(H,21,23)

Beschreibung

Cabozantinib Impurity 3 (CAS 1431468-36-8) is a characterized synthetic and degradation-related byproduct observed during active pharmaceutical ingredient manufacture and stability studies. Analytical characterization typically includes HPLC/UPLC retention behavior, LC-MS and HRMS exact mass confirmation, and 1H and 13C NMR structural assignment to support impurity identification. Quantitative profiling and forced degradation studies inform specification limits and control strategies to mitigate formation during synthesis and storage. Isolation protocols and validated stability-indicating methods enable accurate quantitation and batch release testing. Data support regulatory impurity qualification, root cause analysis, and process optimization to ensure consistent impurity control.